New Drugs

Drug Development through Partnership: Celltrion is actively engaged in licensing in/out through strategic partnerships with the industry, academia, and research centers to expand its pipelines. Through these partnerships, we plan to boost the effectiveness of our new drug R&D projects and revitalize the bio ecosystems in and outside of Korea.

Licensing in

Celltrion works with universities, research centers, and pharmaceutical firms in open innovation projects to secure candidate substances for new drugs and biosimilars under development, and other technologies and intellectual property rights.
Licensing out

Celltrion provides our partners with technologies and intellectual property rights in candidate substances for new drugs and biosimilars, and secure publishing rights, in joint or commissioned research projects.
Co-development

Celltrion works with our partners to increase the chances of success in candidate substance development, reduce development cost, and mitigate other possible risks

CDMO: Contract Development and Management Organization (CDMO) is a co-development model where participants offer and share their expertise in development/production/clinical trial/approval and development costs. Our CDMO partners can commercialize candidate substances for new drugs faster by tapping into our capabilities while we enjoy the benefit of securing the rights to use the substances before others. All in all, CDMO promises faster and dynamic growth for all parties involved.

Celltrion